BFEC
CLLS

Benjamin F. Edwards & Company’s Cellectis CLLS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-300
Closed -$5K – 1841
2019
Q2 		$5K Buy
300
+100
+50% +$1.78K ﹤0.01% 1592
2019
Q1 		$4K Hold
200
– – ﹤0.01% 1519
2018
Q4 		$3K Hold
200
– – ﹤0.01% 1541
2018
Q3 		$6K Buy
+200
New +$5.75K ﹤0.01% 1377

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Benjamin F. Edwards & Company's CLLS Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Cellectis (CLLS) in Q3 2019, closing a stake of 300 shares — an estimated $5K sold.

Benjamin F. Edwards & Company first reported a position in CLLS in Q3 2018 and held it in 4 quarters. The position peaked at $6K in Q3 2018. 64 funds tracked by Wall St. Rank hold CLLS as of Q3 2019.

  • Benjamin F. Edwards & Company reported no remaining Cellectis position as of Q3 2019 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 300 Cellectis shares in Q3 2019, an estimated $5K.
  • Benjamin F. Edwards & Company first reported a position in Cellectis in Q3 2018 and held it in 4 quarters.
  • Benjamin F. Edwards & Company's Cellectis position peaked at $6K in Q3 2018.
  • 64 funds tracked by Wall St. Rank held Cellectis as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.